'김갑성' 기자의 전체기사
-
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lan…
SHANGHAI, Oct. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of relapsed/refractory multiple myeloma (R/R MM) in an investigator-initiated trial (NCT05838131) have been published in The Lancet Haematology. The article was titled "GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
- 김갑성 기자
- 2025-10-08 08:15
-
New Global Beauty & Wellbeing Report unveils Emotional Wellbe…
[ 메디채널 김갑성 기자 ] New proprietary research from Oriflame redefines beauty as a powerful driver of wellbeing STOCKHOLM, Oct. 8, 2025 -- Global beauty and wellbeing company, Oriflame, today releases its first Beauty & Wellbeing Report, revealing a major shift in how women around the world experience and define beauty. Based on a study of 3,500 women across seven countries, the report highlights the powerful role beauty plays in enhancing emotional wellbeing, self-confidence, and daily self-care. The findings reveal that beauty today is not about chasing perfection, but about f
- 김갑성 기자
- 2025-10-08 07:01
-
Global Direct Selling Leader QNET Celebrates 27 Years, Showc…
PENANG, Malaysia, Oct. 8, 2025 -- QNET, a leading global lifestyle and wellness direct selling company, concluded its spectacular 27th-anniversary convention, V-Malaysia 2025, in Penang this week. The event, endorsed by Tourism Malaysia, welcomed over 10,000 independent distributors from more than 30 countries, serving as a powerful testament to the company's global community and the significant economic benefits of its flagship events. Held for the 13th consecutive year in Penang, the five-day convention underscored Malaysia's position as a premier MICE (Meetings, Incentives,
- 김갑성 기자
- 2025-10-08 06:06
-
Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-…
BRISBANE, Australia, Oct. 8, 2025 -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed recruitment for its first-in-human Phase I clinical trial of CYT-101. CYT-101 is a novel off-the-shelf, HLA-matched CMV-specific T cell therapy for the treatment of glioblastoma multiforme (GBM) and other solid cancers. GBM is an aggressive brain cancer and one of the deadliest solid cancers in adults, with limited treatment options available. The unique advantage of targeting CMV antigens
- 김갑성 기자
- 2025-10-08 06:00
-
밀리켄앤드컴퍼니, Millad ClearX™ 9000 출시: 폴리프로필렌용 차세대 투명화 기술
첨가제 사용량을 줄여 탁월한 투명도 구현 - 생산 공정 간소화 및 가공업·수지 생산업에 다양한 배합 옵션 제공 스파턴버그, 사우스캐롤라이나, 2025년 10월 8일 -- 밀리켄앤드컴퍼니(Milliken & Company)가 폴리프로필렌(PP)용 차세대 투명화 기술인 Millad ClearX™ 9000을 새롭게 출시했다고 발표했다. 이 제품은 첨가제 사용량을 줄이면서도 초고투명성을 구현하도록 설계됐다. Millad ClearX™ 9000은 식품 포장, 가정용 저장 용기, 의료용 제품 등 사용에 이상적이며, 투명한 PP 제품의 가치, 심미성, 공정 효율성 측면에서 새로운 기준을 제시한다. 입증된 Millad® 플랫폼을 기반으로 구축된 Millad ClearX™ 9000은 제조업체에 다음과 같은 고급 솔루션을 제공한다. 첨가제 사용 효율을 높여 초고투명 PP를 구현함으로써, 필요한 투명화 첨가제의 양을 감소시킨다. 추출 및 용출 비율을 낮춰, 식품 접촉용 및 의료용 PP 포장과 부품에서 안전성을 강화한다. 이전 세대 대비 가공 호환성을 개선해 운영 효율성 향
- 김갑성 기자
- 2025-10-08 01:33
-
An Era Where Meditation Becomes a Quantifiable Achievemen…
TOKYO, Oct. 7, 2025 -- Meditation entered a new era as the World Meditation League (WML), and All Here introduced Japan's first Tokyo Quantified Meditation Challenge in the gardens of Happo-en. This unprecedented event took meditation beyond personal introspection — transforming it into a measurable, observable, and competitive discipline through neuroscience. For the first time, audiences witnessed meditation in real time, as brain activity, attention, self-awareness and inner silence were displayed as quantifiable data on screen. Technology × Archi
- 김갑성 기자
- 2025-10-07 21:24
-
Metabolon's Metabolomics Services Now Cited in More Than…
Metabolon's best-in-class metabolomics leadership accelerates as metabolomics becomes a standard inclusion in global multiomics studies MORRISVILLE, N.C., Oct. 7, 2025 -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced that its metabolomics services have now been cited in more than 4,000 peer-reviewed publications, far more than any other metabolomics provider in the life sciences industry. Publications refer
- 김갑성 기자
- 2025-10-07 21:00
-
ZEISS expands DORC portfolio and further strengthens digital…
Showcasing at AAO 2025: NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING & PATHOLOGY DETECTION: Showcasing optical coherence tomography angiography (OCT-A) with ZEISS CIRRUS AngioPlex® with noninvasive imaging of the retinal and choroidal vasculature; now with 510k clearance and CE approval, ICGA for CLARUS® 700 offers FA + ICG simultaneous capture. OPTIMIZED RETINAL SURGICAL EXPERIENCE: Announcing updates to DORC instruments to expand surgeons' options, including new gauges added to the range of subretinal injection cannulae and a new Midfield endoillu
- 김갑성 기자
- 2025-10-07 21:00
-
Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in th…
TOKYO, Oct. 7, 2025 -- Celaid Therapeutics Inc. ("Celaid"), today announced the successful completion of the 1st Close of its Series B financing round, raising JPY 1.055 billion (USD 7.2 million) from venture capital firms and the Japan Agency for Medical Research and Development (AMED). Including grants and subsidies, Celaid's cumulative funding has reached JPY 2.52 billion (USD 17.14 million). This financing reflects recognition of the progress in the company's lead pipeline program CLD-001, a novel ex vivo-expanded hematopoietic stem cell (HSC) therapy for severe pediatric
- 김갑성 기자
- 2025-10-07 21:00
-
Kazia Therapeutics Announces Collaboration and In-Lic…
SYDNEY, Oct. 7, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader currently in development and represents a new and innovative frontier of cancer immunotherapy. About PD-L1 Degradation and NDL2 Cancer cells frequently express PD-L1 protein to evade immune attack. When PD-L1 on a tumor cell surface bin
- 김갑성 기자
- 2025-10-07 20:30
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-16_TUE
- DIFC, 헤지펀드 매니저 위한 글로벌 5대 허브로 도약 - 센터 등록 헤지펀드 100개 넘어 14:18
- CTicket Selected as Exclusive Ticketing Partner for T1 Vietnam Fanmeeting in Vietnam 14:03
- Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases 12:55
- Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion 12:23
- Global forum discusses value of Spring Festival 12:02
- BREAKWATER ENERGY HOLDINGS S.À R.L. ANNOUNCES PRICING OF AN ADDITIONAL $75 MILLION OF ITS 9¼% SENIOR SECURED NOTES DUE 2030 11:16
- Toys"R"Us Opens IP Collection Flagship Store at Suria KLCC 10:30
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 16일 15시 50분